In today’s briefing:
- Japan Weekly | Relo, KHI, Kose, Yokogawa
- Themes of India: Future of Data Centre in India
- AUCTUS ON FRIDAY – 10/05/2024
- Shroom Shmooz – How Valid Are ICER’s Concerns About MAPS’ MDMA- AT Trials?
- Water Tower Hour Recap – Cannabis Rescheduling Review with Poseidon
Japan Weekly | Relo, KHI, Kose, Yokogawa
- Japanese equity indices and 10-year JGB yields remain flat as overseas markets benefit from positive earnings and softer labor data in the US.
- Topix 500 earnings reports influence individual equity movements with around 50% reported; remainder expected next week.
- Notable stock movements include Relo Group (+22%), Kose (+22%), and Kawasaki Heavy Industries (+21%), with earnings exceeding expectations, while Seibu Holdings (-16%) faces uncertainties in its real estate strategy.
Themes of India: Future of Data Centre in India
- India, with high data generation but low data center capacity, is attracting investments in India.
- Rapid digital transformation and lower setup costs are driving India’s data center market growth, offering significant investment opportunities.
- Understanding India’s potential as a data center hub highlights investment prospects and the need for sustainable practices in infrastructure development.
AUCTUS ON FRIDAY – 10/05/2024
- GeoPark (GPRK US)C; target price of US$26 per share: More favourable offtake contract in Colombia – GeoPark has signe da new offtake contract with Vitol for a minimum of 20 mbbl/d.
- The agreement improves GeoPark’s price realizations by US$0.15/bbl vs the current agreement.
- As part of this transaction, GeoPark will obtain immediate access to committed funding from Vitol for up to US$300 mm, with an option to increase by another US$200 mm for a total of US$500 mm, in prepaid future oil sales over the period of the offtake contract.
Shroom Shmooz – How Valid Are ICER’s Concerns About MAPS’ MDMA- AT Trials?
- ICER pours cold water on MAPS’ MDMA-AT candidate for treating PTSD.
- In March, the Institute fo Clinical and Economic Review (ICER) published its draft evidence report on MAPS’ (aka Lykos Therapeutics) Phase III clinical trials.
- The draft report, which is not the final version, controversially questions the integrity of the studies and validity of MAPS’ reported results.
Water Tower Hour Recap – Cannabis Rescheduling Review with Poseidon
- Poseidon co-founders Emily and Morgan Paxhia joined us on the Water Tower Hour podcast to discuss the rescheduling news.
- Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website.
- On April 30, 2024, the DEA reportedly agreed with the HHS recommendation to reclassify cannabis from Schedule I to Schedule III.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
